PA8546701A1 - Nueva composicion farmaceutica - Google Patents
Nueva composicion farmaceuticaInfo
- Publication number
- PA8546701A1 PA8546701A1 PA20028546701A PA8546701A PA8546701A1 PA 8546701 A1 PA8546701 A1 PA 8546701A1 PA 20028546701 A PA20028546701 A PA 20028546701A PA 8546701 A PA8546701 A PA 8546701A PA 8546701 A1 PA8546701 A1 PA 8546701A1
- Authority
- PA
- Panama
- Prior art keywords
- pharmaceutical composition
- ester
- new pharmaceutical
- sacarose
- preferibly
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
LA PRESENTE INVENCION SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE UN INHIBIDOR DE LIPASAS, PREFERIBLEMENTE ORLISTAT, CON UN PUNTO DE FUSION MAYOR O IGUAL A 37°C, UN ESTER DE ACIDO GRASO DE SACAROSA EN DONDE EL ESTER DE ACIDO GRASO DE SACAROSA ES UN MONO-, DI-, TRI- O TETRA-ESTER, Y OPCIONALMENTE UNO O MAS EXCIPIENTES FARMACEUTICAMENTE ACEPTABLES.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01113793 | 2001-06-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
PA8546701A1 true PA8546701A1 (es) | 2003-01-24 |
Family
ID=8177654
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PA20028546701A PA8546701A1 (es) | 2001-06-06 | 2002-06-04 | Nueva composicion farmaceutica |
Country Status (40)
Country | Link |
---|---|
US (4) | US20030027786A1 (es) |
EP (1) | EP1399152B1 (es) |
JP (2) | JP4261337B2 (es) |
KR (1) | KR100753729B1 (es) |
CN (1) | CN1514725B (es) |
AR (1) | AR034355A1 (es) |
AT (1) | ATE356622T1 (es) |
AU (1) | AU2002257817B2 (es) |
BG (1) | BG66346B1 (es) |
BR (1) | BRPI0210266B1 (es) |
CA (1) | CA2448030C (es) |
CO (1) | CO5540293A2 (es) |
CY (1) | CY1107641T1 (es) |
CZ (1) | CZ299948B6 (es) |
DE (1) | DE60218845T2 (es) |
DK (1) | DK1399152T3 (es) |
EC (1) | ECSP034871A (es) |
ES (1) | ES2282415T3 (es) |
GT (1) | GT200200106A (es) |
HK (1) | HK1067312A1 (es) |
HR (1) | HRP20030983B1 (es) |
HU (1) | HU230405B1 (es) |
IL (2) | IL158908A0 (es) |
JO (1) | JO2455B1 (es) |
MA (1) | MA27031A1 (es) |
ME (1) | ME00579B (es) |
MX (1) | MXPA03011191A (es) |
MY (1) | MY161871A (es) |
NO (1) | NO328006B1 (es) |
NZ (1) | NZ529630A (es) |
PA (1) | PA8546701A1 (es) |
PE (1) | PE20030230A1 (es) |
PL (1) | PL215266B1 (es) |
PT (1) | PT1399152E (es) |
RS (1) | RS50713B (es) |
RU (1) | RU2271808C2 (es) |
SI (1) | SI1399152T1 (es) |
SK (1) | SK287602B6 (es) |
WO (1) | WO2002098412A1 (es) |
ZA (1) | ZA200309007B (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030027786A1 (en) * | 2001-06-06 | 2003-02-06 | Karsten Maeder | Lipase inhibiting composition |
US8372430B2 (en) * | 2002-12-17 | 2013-02-12 | The Procter & Gamble Company | Compositions, methods, and kits useful for the alleviation of gastrointestinal effects |
FI20045076A (fi) * | 2004-03-15 | 2005-09-16 | Bioferme Oy | Funktionaalinen elintarvike |
KR100910000B1 (ko) * | 2005-05-13 | 2009-07-29 | 씨제이제일제당 (주) | 리파아제 저해제 함유 약학 조성물 |
WO2006132440A1 (ja) * | 2005-06-09 | 2006-12-14 | Takeda Pharmaceutical Company Limited | 固形製剤 |
US20070111914A1 (en) * | 2005-11-16 | 2007-05-17 | Conopco, Inc., D/B/A Unilever, A Corporation Of New York | Environmentally friendly laundry method and kit |
KR101252635B1 (ko) * | 2006-04-20 | 2013-04-10 | (주)아모레퍼시픽 | 리파아제 저해제 및 친유성 오일흡수제를 포함하는 약학조성물 및 이로부터 제조된 경구 투여용 제제 |
EP1872777A1 (en) * | 2006-06-27 | 2008-01-02 | LEK Pharmaceuticals D.D. | Pharmaceutical composition comprising tetrahydrolipstatin |
GB0618725D0 (en) * | 2006-09-23 | 2006-11-01 | Jagotec Ag | Composition containing inhibitors of gastro-intestinal lipase |
PL216542B1 (pl) | 2008-03-20 | 2014-04-30 | Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna | Sposób wytwarzania stabilnej kompozycji orlistatu w postaci kapsułkowanego proszku |
US8309107B2 (en) * | 2008-10-06 | 2012-11-13 | Banner Pharmacaps, Inc. | Stable solutions of orlistat for pharmaceutical dosage forms |
FR2994386B1 (fr) * | 2012-08-07 | 2016-06-24 | Thorel Jean-Noel | Inhibition de l'adhesion de micro-organismes pathogenes par un ester de saccharose et/ou de sorbitan dans le traitement cosmetique de l'atopie cutanee |
US10743813B2 (en) | 2014-09-11 | 2020-08-18 | Rattan Nath | Diabetes control using postprandial feedback |
CN104546768B (zh) * | 2014-12-30 | 2017-06-16 | 重庆植恩药业有限公司 | 含有脂肪酶抑制剂的咀嚼片组合物及其制备方法 |
MA45430A (fr) | 2015-10-23 | 2019-05-01 | Erx Pharmaceuticals Inc | Analogues de célastrol |
CN113151373B (zh) * | 2021-03-09 | 2023-07-04 | 武汉臻治生物科技有限公司 | 一种具有抗菌及抗肿瘤活性的蔗糖单酯的制备方法及其应用 |
KR102637596B1 (ko) | 2022-03-18 | 2024-02-19 | (주)보노보씨 | 기능성 목공교구 |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1965133A1 (de) | 1969-12-27 | 1971-07-22 | Merck Patent Gmbh | Verfahren zur Herstellung pharmazeutischer Zubereitungen |
US4148924A (en) * | 1977-06-13 | 1979-04-10 | The Procter & Gamble Company | Dermatological compositions |
CA1247547A (en) * | 1983-06-22 | 1988-12-28 | Paul Hadvary | Leucine derivatives |
CA1328881C (en) | 1984-12-21 | 1994-04-26 | Pierre Barbier | Process for the manufacture of oxetanones |
CA1270837A (en) | 1984-12-21 | 1990-06-26 | Hoffmann-La Roche Limited | Oxetanones |
NL8600050A (nl) | 1986-01-13 | 1987-08-03 | Sanico Nv | Farmaceutisch preparaat met vertraagde afgifte van het werkzame bestanddeel en werkwijze voor de bereiding er van. |
EP0271963B1 (en) * | 1986-12-19 | 1993-07-21 | The Procter & Gamble Company | Food compositions with superior blood cholesterol lowering properties |
JP2748597B2 (ja) | 1989-09-28 | 1998-05-06 | 三菱化学株式会社 | 食品劣化抑制剤 |
CA2035972C (en) | 1990-02-23 | 2006-07-11 | Martin Karpf | Process for the preparation of oxetanones |
JP3112473B2 (ja) | 1990-10-18 | 2000-11-27 | オリンパス光学工業株式会社 | 屈折率分布型光学素子の製造方法 |
US5294451A (en) * | 1991-03-29 | 1994-03-15 | Curtice-Burns, Inc. | Fat substitute compositions having reduced laxative effects |
US5274143A (en) | 1991-07-23 | 1993-12-28 | Hoffmann-La Roche Inc. | Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione |
FR2735658B1 (fr) * | 1995-06-21 | 1997-09-12 | Capsulis | Encapsulation de composes a usage alimentaire par des tensioactifs |
CA2098167C (en) * | 1992-06-24 | 2006-12-19 | Dorothea Isler | Foodstuffs and feedstuffs containing a lipase inhibitor |
US6004996A (en) | 1997-02-05 | 1999-12-21 | Hoffman-La Roche Inc. | Tetrahydrolipstatin containing compositions |
US6267952B1 (en) | 1998-01-09 | 2001-07-31 | Geltex Pharmaceuticals, Inc. | Lipase inhibiting polymers |
CA2340052C (en) | 1998-08-14 | 2007-05-29 | F. Hoffmann-La Roche Ag | Pharmaceutical compositions containing lipase inhibitors and chitosan |
AU761351B2 (en) | 1998-08-14 | 2003-06-05 | Cheplapharm Arzneimittel Gmbh | Pharmaceutical compositions containing lipase inhibitors |
AU1031500A (en) | 1998-11-03 | 2000-05-22 | Dandy A/S | Sucrose fatty acid esters for use as increased release of active ingredients |
GB9900416D0 (en) | 1999-01-08 | 1999-02-24 | Alizyme Therapeutics Ltd | Inhibitors |
AR025609A1 (es) * | 1999-09-13 | 2002-12-04 | Hoffmann La Roche | Formulaciones lipidas solidas |
AR025587A1 (es) * | 1999-09-13 | 2002-12-04 | Hoffmann La Roche | Formulaciones en dispersion que contienen inhibidores de lipasa |
US6348492B1 (en) | 1999-10-29 | 2002-02-19 | 2Pro Chemical | Oxetanone derivatives |
AU1347701A (en) | 1999-10-29 | 2001-05-14 | John Jason Gentry Mullins | Oxetanone derivatives |
JP4149803B2 (ja) * | 2000-06-27 | 2008-09-17 | エフ.ホフマン−ラ ロシュ アーゲー | 組成物の調製方法 |
BR0112800A (pt) | 2000-07-28 | 2003-07-01 | Hoffmann La Roche | Utilização de um inibidor de lìpases e de um sequestrante de ácido de bìlis farmaceuticamente aceitáveis e processo para a prevenção e tratamento de enfermidades associadas com altos nìveis de colesterol de plasma |
US20030027786A1 (en) * | 2001-06-06 | 2003-02-06 | Karsten Maeder | Lipase inhibiting composition |
US6534097B1 (en) * | 2002-07-11 | 2003-03-18 | Betty Baggott | Pest repellent |
-
2002
- 2002-05-23 US US10/154,494 patent/US20030027786A1/en not_active Abandoned
- 2002-05-29 HU HU0401208A patent/HU230405B1/hu unknown
- 2002-05-29 SK SK1609-2003A patent/SK287602B6/sk not_active IP Right Cessation
- 2002-05-29 CA CA002448030A patent/CA2448030C/en not_active Expired - Lifetime
- 2002-05-29 IL IL15890802A patent/IL158908A0/xx active IP Right Grant
- 2002-05-29 ME MEP-2008-904A patent/ME00579B/me unknown
- 2002-05-29 DE DE60218845T patent/DE60218845T2/de not_active Expired - Lifetime
- 2002-05-29 JP JP2003501451A patent/JP4261337B2/ja not_active Expired - Fee Related
- 2002-05-29 WO PCT/EP2002/005889 patent/WO2002098412A1/en active IP Right Grant
- 2002-05-29 KR KR1020037015985A patent/KR100753729B1/ko active IP Right Grant
- 2002-05-29 EP EP02727607A patent/EP1399152B1/en not_active Expired - Lifetime
- 2002-05-29 PL PL366890A patent/PL215266B1/pl unknown
- 2002-05-29 AT AT02727607T patent/ATE356622T1/de active
- 2002-05-29 SI SI200230524T patent/SI1399152T1/sl unknown
- 2002-05-29 BR BRPI0210266A patent/BRPI0210266B1/pt not_active IP Right Cessation
- 2002-05-29 PT PT02727607T patent/PT1399152E/pt unknown
- 2002-05-29 CZ CZ20033525A patent/CZ299948B6/cs not_active IP Right Cessation
- 2002-05-29 MX MXPA03011191A patent/MXPA03011191A/es active IP Right Grant
- 2002-05-29 RU RU2003136728/15A patent/RU2271808C2/ru active
- 2002-05-29 NZ NZ529630A patent/NZ529630A/en not_active IP Right Cessation
- 2002-05-29 CN CN028114957A patent/CN1514725B/zh not_active Expired - Lifetime
- 2002-05-29 AU AU2002257817A patent/AU2002257817B2/en not_active Expired
- 2002-05-29 RS YUP-960/03A patent/RS50713B/sr unknown
- 2002-05-29 DK DK02727607T patent/DK1399152T3/da active
- 2002-05-29 ES ES02727607T patent/ES2282415T3/es not_active Expired - Lifetime
- 2002-06-02 JO JO200254A patent/JO2455B1/en active
- 2002-06-04 PA PA20028546701A patent/PA8546701A1/es unknown
- 2002-06-04 AR ARP020102074A patent/AR034355A1/es not_active Application Discontinuation
- 2002-06-04 MY MYPI20022058A patent/MY161871A/en unknown
- 2002-06-05 GT GT200200106A patent/GT200200106A/es unknown
- 2002-06-05 PE PE2002000472A patent/PE20030230A1/es active IP Right Grant
-
2003
- 2003-11-17 IL IL158908A patent/IL158908A/en unknown
- 2003-11-19 ZA ZA2003/09007A patent/ZA200309007B/en unknown
- 2003-11-26 HR HR20030983A patent/HRP20030983B1/xx not_active IP Right Cessation
- 2003-11-28 NO NO20035318A patent/NO328006B1/no not_active IP Right Cessation
- 2003-12-01 EC EC2003004871A patent/ECSP034871A/es unknown
- 2003-12-02 CO CO03106075A patent/CO5540293A2/es active IP Right Grant
- 2003-12-03 MA MA27421A patent/MA27031A1/fr unknown
- 2003-12-05 BG BG108421A patent/BG66346B1/bg unknown
-
2004
- 2004-12-23 US US11/019,865 patent/US8039508B2/en not_active Expired - Lifetime
- 2004-12-30 HK HK04110347.5A patent/HK1067312A1/xx not_active IP Right Cessation
-
2007
- 2007-05-29 CY CY20071100716T patent/CY1107641T1/el unknown
-
2008
- 2008-11-12 JP JP2008289389A patent/JP2009108076A/ja active Pending
-
2011
- 2011-08-19 US US13/213,379 patent/US8343543B2/en not_active Expired - Lifetime
-
2012
- 2012-11-26 US US13/684,698 patent/US20130079391A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PA8546701A1 (es) | Nueva composicion farmaceutica | |
AR018221A1 (es) | Composiciones herbicidas que contienen aceites esenciales de plantas y mixturas o mezclas de los mismos | |
ATE374602T1 (de) | Orale kapselformulierung mit verbesserter physikalischer stabilität | |
ATE506054T1 (de) | Feste formulierungen von ospemifen | |
HN2003000184A (es) | Preparaciones acidas de insulina con estabilidad mejorada | |
HN2001000244A (es) | Inhibidores de espiropirimidin - 2, 4, 6 - triona metaloproteinasas. | |
DK1313467T3 (da) | Hidtil ukendte farmaceutiske præparater til indgivelse af N-0923 | |
GT200200133A (es) | Formulaciones de latex libres de aceleradores, metodos para hacer dichas formulaciones y articulos hechos de los mismos | |
GT200300054A (es) | Compuestos que modulan la actividad de ppar | |
ATE349207T1 (de) | Verstärkte wirkung mehrfach ungesättigter fettsäuren | |
BR0208117A (pt) | Lançador aspersor e método de aspersão | |
HN2002000198A (es) | Composiciones farmaceuticas de amlodipina y atorvastatina | |
HN2001000224A (es) | Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos. | |
WO2006081364A3 (en) | Formulations for injection of catecholic butanes, including ndga compounds, into animals | |
AR025609A1 (es) | Formulaciones lipidas solidas | |
HN2003000038A (es) | Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico | |
EA200401183A1 (ru) | Применение ингибиторов il-18 в качестве диагностического маркера | |
ITTO20020795A1 (it) | Impiego di un composto di tetrabenzilestere come pesticida e relativi procedimenti di utilizzo di tale composto. | |
UY27321A1 (es) | Nueva composición farmacéutica | |
AR040600A1 (es) | Composicion farmaceutica estable que comprende eritropoietina | |
WO2002026324A3 (en) | Tocol-based compositions containing amiodarone | |
ECSP045086A (es) | Composiciones farmaceuticas que contienen macrolidos | |
ATE550051T1 (de) | Wirkstoffabgebende gefässprothese | |
AR033503A1 (es) | Un derivado de 3-metileno esteroide, una composicion farmaceutica que lo comprende, y uso de un derivado de 3-metileno esteroide | |
HN2000000279A (es) | Composiciones farmaceuticas que proporcionan concentraciones potenciales de farmaco. |